The Tissue Systems Pathology Test Outperforms Pathology Review in Risk Stratifying Patients With Low-Grade Dysplasia.

Publication

The Tissue Systems Pathology Test Outperforms Pathology Review in Risk Stratifying Patients With Low-Grade Dysplasia.

Journal Paper/Review - Aug 30, 2023

Khoshiwal Amir M, Frei Nicola Fabian, Pouw Roos E, TissueCypher SURF LGD Study Pathologists Consortium, Smolko Christian, Arora Meenakshi, Siegel Jennifer J, Duits L C, Critchley-Thorne Rebecca J, Thangaiah Judith Jebastin

Citation

Khoshiwal A, Frei N, Pouw R, TissueCypher SURF LGD Study Pathologists Consortium, Smolko C, Arora M, Siegel J, Duits L, Critchley-Thorne R, Thangaiah J. The Tissue Systems Pathology Test Outperforms Pathology Review in Risk Stratifying Patients With Low-Grade Dysplasia. Gastroenterology 2023; 165:1168-1179.e6.

Type

Journal Paper/Review (English)

Journal

Gastroenterology 2023; 165

Publication Date

Aug 30, 2023

Issn Electronic

1528-0012

Pages

1168-1179.e6

Brief description/objective

Low-grade dysplasia (LGD) is associated with an increased risk of progression in Barrett's esophagus (BE); however, the diagnosis of LGD is limited by substantial interobserver variability. Multiple studies have shown that an objective tissue systems pathology test (TissueCypher Barrett's Esophagus Test, TSP-9), can effectively predict neoplastic progression in patients with BE. This study aimed to compare the risk stratification performance of the TSP-9 test vs benchmarks of generalist and expert pathology.